DOTmed Home MRI Oncology Ultrasound Molecular Imaging X-Ray Cardiology Health IT Business Affairs
News Home Parts & Service Operating Room CT Women's Health Proton Therapy Endoscopy HTMs Mobile Imaging
SEARCH
Endroit courant :
>
> This Story

starstarstarstarstar (1)
Ouverture ou Registre to rate this News Story
Forward Printable StoryPrint Comment

 

Business Affairs Homepage

Olympus expands its EndoTherapy product line One new device and two business deals

UK has third lowest number of radiologists per population out of 31 EU countries Nearly two-thirds of posts remained unfilled for 12 months or longer in 2016

Survey finds medical devices not meeting provider expectations A call for higher-quality clinical evidence, flexible contract options and better customer service

European Society of Radiology calls for diagnostics to be better represented in value-based care Diagnosis 'is the basis for any treatment decision'

GE Healthcare receives Carequality certification Centricity customers can share data among multiple providers

Canon elaborates on financial goals with Toshiba Medical in the fold 'Launching into the global health market ... in one fell swoop'

Former Cleveland Clinic Innovations director pleads guilty to fraud Scheme cost the institution over $2.7 million

NuVasive files lawsuit against former vice chairman Alleges breach of fiduciary duties and violation of contractual obligations

Blue Earth Diagnostics inks Axumin deal with Seibersdorf Laboratories Manufacturing and distribution in certain European countries

Philips to halt production of external defibrillators in two U.S. facilities OEM looks ahead, calling consent decree 'consequence of past sins'

SHINE faces money-raising woes, hopes to build prototype first

par Thomas Dworetzky , Contributing Reporter
SHINE Medical Technologies has hit a money-raising snag – and now wants to build a prototype of its full-scale radioisotope-producing facility in Janesville, Wisconsin.

Talks are now underway between the company and the city to secure additional funding, city economic development director Gale Price told GazetteXtra.com.

Story Continues Below Advertisement

CT, MRI, NM, SPECT/CT, PET & PET/CT service, refurbished systems and parts

Accelerate your ROI with our Black Diamond Certified refurbished systems. One year warranty - ISO 13485 Certified - FDA registered - Over 65k parts in inventory DOTmed Certified



This could stall by three-to-six months the goal of commercial Molybdenum-99 production at SHINE's to-be-built $100 million, 57,000 square-foot main plant in Janesville, Wisconsin, until 2020 – most recently scheduled for mid-2019.

Building a prototype “wasn't part of the original plan,” Katrina Pitas, SHINE Vice President, told the news site, adding that, “frankly, the reason we're breaking ground on that facility instead of the manufacturing facility is that we have raised money slower than we'd intended.”

Pitas told The Gazette that SHINE needs to raise more private equity before beginning construction of the full-scale manufacturing plant. Last year the company raised $18 million in private funding and was also awarded $10 million from the DOE as part of a $20 million cooperative agreement.

The smaller facility is expected to demonstrate the appeal of the full-scale production plant to potential investors.

“We'll say, 'We've already produced moly 99. Here's the technology. All we have to do is build eight more accelerators.' Also, at the same time, we're really moving toward production. It's a path that helps us serve multiple purposes, but really, it helps us get closer to [Mo-99] commercialization," Pitas said.

The present plan is to build the 11,500-square-foot prototype on land south of the site slated for the full-scale plant.

If the prototype moves ahead, SHINE could begin its construction and start testing in 2018.

Should the prototype be successful in convincing investors, it will still be useful even after the full plant is built. “I don't think we'll ever sell moly-99 out of that building,” advised Pitas in reference to the prototype, “but we will be operating and testing at it.

The SHINE technology has been in development for a number of years. Its use of particle accelerators instead of nuclear reactors is of particular importance as a number of overseas reactors that make Mo-99 — such as Chalk River in Ontario, Canada — are aging and shutting down.

GE Healthcare and SHINE Medical Technologies announced in November 2015 that GE’s DRYTEC Technetium-99m (Tc-99m) generator had successfully produced pharmaceutical-grade Tc-99m using SHINE’s process to produce Mo-99.
  Pages: 1 - 2 >>

Business Affairs Homepage


You Must Be Logged In To Post A Comment

Publicité
Développez la notoriété de votre marque
Enchères + Ventes Privées
Obtenir le meilleur prix
Acheter des équipement / pièces
Trouver le meilleur prix
Infos du jour
Lire Les dernières nouvelles
Annuaire
Consulter tous les utilisateurs DOTmed
Éthique concernant DOTmed
Voir notre programme d'éthique
L'or partie le programme de fournisseur
Recevoir des demandes PH
Programme de marchand de service d'or
Recevoir des demandes
Fournisseurs de soins de santé
Voir tous les outils des HCP (abréviation pour les professionnels de la santé)
Les travaux/Formation
Trouver / combler un poste
Parts Hunter +EasyPay
Obtenir des devis de pièces
Certification Récentes
Voir les utilisateurs récemment certifiés
Evaluation Récentes
Voir les utilisateurs récemment certifiés
Central de location
Louer de l’équipement à moindre prix
Vendre des équipements / pièces
Obtenir le maximum d'argent
Service le forum de techniciens
Trouver de l'aide et des conseils
Simple demande de propositions
Obtenir des devis pour des appareils
Expo Virtuelle
Trouver des services d'appareils
L'Access et l'utilisation de cet emplacement est sujet aux modalités et aux conditions du notre de nos MENTIONS LEGALES & DONNEES PERSONELLES
Propriété de et classe des propriétaires DOTmedà .com, inc. Copyright ©2001-2017 DOTmed.com, Inc.
TOUS DROITS RÉSERVÉS